Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
Cross, N C P ; White, H E ; Colomer, D ; Ehrencrona, Hans LU
; Foroni, L
; Gottardi, E
; Lange, T
; Lion, T
; Machova Polakova, K
and Dulucq, S
, et al.
(2015)
In Leukemia
29(5).
p.999-1003
- Abstract
- Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to... (More)
- Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.Leukemia advance online publication, 27 February 2015; doi:10.1038/leu.2015.29. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5145410
- author
- Cross, N C P
; White, H E
; Colomer, D
; Ehrencrona, Hans
LU
; Foroni, L
; Gottardi, E
; Lange, T
; Lion, T
; Machova Polakova, K
and Dulucq, S
, et al. (More)
- Cross, N C P
; White, H E
; Colomer, D
; Ehrencrona, Hans
LU
; Foroni, L
; Gottardi, E
; Lange, T
; Lion, T
; Machova Polakova, K
; Dulucq, S
; Martinelli, G
; Oppliger Leibundgut, E
; Pallisgaard, N
; Barbany, G
; Sacha, T
; Talmaci, R
; Izzo, B
; Saglio, G
; Pane, F
; Müller, M C
and Hochhaus, A
(Less)
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia
- volume
- 29
- issue
- 5
- pages
- 999 - 1003
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:25652737
- wos:000354070600001
- scopus:84929265404
- pmid:25652737
- ISSN
- 1476-5551
- DOI
- 10.1038/leu.2015.29
- language
- English
- LU publication?
- yes
- id
- 97d0f73e-90d7-4b1e-8d52-285204e168ec (old id 5145410)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25652737?dopt=Abstract
- date added to LUP
- 2016-04-01 10:37:27
- date last changed
- 2022-04-20 03:46:34
@article{97d0f73e-90d7-4b1e-8d52-285204e168ec,
abstract = {{Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.Leukemia advance online publication, 27 February 2015; doi:10.1038/leu.2015.29.}},
author = {{Cross, N C P and White, H E and Colomer, D and Ehrencrona, Hans and Foroni, L and Gottardi, E and Lange, T and Lion, T and Machova Polakova, K and Dulucq, S and Martinelli, G and Oppliger Leibundgut, E and Pallisgaard, N and Barbany, G and Sacha, T and Talmaci, R and Izzo, B and Saglio, G and Pane, F and Müller, M C and Hochhaus, A}},
issn = {{1476-5551}},
language = {{eng}},
number = {{5}},
pages = {{999--1003}},
publisher = {{Nature Publishing Group}},
series = {{Leukemia}},
title = {{Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.}},
url = {{https://lup.lub.lu.se/search/files/2000419/8051866}},
doi = {{10.1038/leu.2015.29}},
volume = {{29}},
year = {{2015}},
}